CA2280727A1 - Bicyclic amino acids - Google Patents

Bicyclic amino acids Download PDF

Info

Publication number
CA2280727A1
CA2280727A1 CA002280727A CA2280727A CA2280727A1 CA 2280727 A1 CA2280727 A1 CA 2280727A1 CA 002280727 A CA002280727 A CA 002280727A CA 2280727 A CA2280727 A CA 2280727A CA 2280727 A1 CA2280727 A1 CA 2280727A1
Authority
CA
Canada
Prior art keywords
amino acids
compounds
bicyclic amino
diseases
infarcts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002280727A
Other languages
French (fr)
Other versions
CA2280727C (en
Inventor
Beate Diefenbach
Simon L. Goodman
Joachim Marz
Peter Raddatz
Friedrich Rippmann
Matthias Wiesner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2280727A1 publication Critical patent/CA2280727A1/en
Application granted granted Critical
Publication of CA2280727C publication Critical patent/CA2280727C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to compounds of formula (1), wherein X, Y, Z, R1, R2, R3, R4, R5, R7, R8, R11, m and n have the meaning cited in Claim 1, and to their physiologically acceptable salts. Said compounds can be used as integrin inhibitors, specially for prophylaxis and treatment of circulatory diseases, thrombosis, infarcts, coronary heart diseases, arteriosclerosis, osteoporosis, pathological symptoms sustained or propagated by angiogenesis and in tumor therapy.
CA002280727A 1997-02-13 1998-02-06 Bicyclic amino acids Expired - Fee Related CA2280727C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19705450.1 1997-02-13
DE19705450A DE19705450A1 (en) 1997-02-13 1997-02-13 Bicyclic aromatic amino acids
PCT/EP1998/000636 WO1998035949A1 (en) 1997-02-13 1998-02-06 Bicyclic amino acids

Publications (2)

Publication Number Publication Date
CA2280727A1 true CA2280727A1 (en) 1998-08-20
CA2280727C CA2280727C (en) 2008-05-06

Family

ID=7820093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002280727A Expired - Fee Related CA2280727C (en) 1997-02-13 1998-02-06 Bicyclic amino acids

Country Status (25)

Country Link
EP (1) EP0964856B1 (en)
JP (1) JP4327257B2 (en)
KR (1) KR20000071030A (en)
CN (1) CN1085205C (en)
AR (1) AR010894A1 (en)
AT (1) ATE225776T1 (en)
AU (1) AU735313B2 (en)
BR (1) BR9807345A (en)
CA (1) CA2280727C (en)
CY (1) CY2341B1 (en)
CZ (1) CZ297366B6 (en)
DE (2) DE19705450A1 (en)
DK (1) DK0964856T3 (en)
ES (1) ES2183332T3 (en)
HU (1) HUP0001138A3 (en)
ID (1) ID22533A (en)
NO (1) NO313289B1 (en)
PL (1) PL335101A1 (en)
PT (1) PT964856E (en)
RU (1) RU2187506C2 (en)
SI (1) SI0964856T1 (en)
SK (1) SK284646B6 (en)
TR (1) TR199901962T2 (en)
WO (1) WO1998035949A1 (en)
ZA (1) ZA981178B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US9403830B2 (en) 2012-07-17 2016-08-02 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US9573957B2 (en) 2013-07-15 2017-02-21 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US9662339B2 (en) 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063790A1 (en) * 1996-05-31 2004-04-01 The Scripps Research Institute Methods for inhibition of angiogenesis
NZ507222A (en) 1998-04-09 2003-05-30 Meiji Seika Kaisha Aminopiperidine derivatives useful as integrin antagonists
CZ20013678A3 (en) 1999-04-13 2002-07-17 Basf Aktiengesellschaft Ligands of integrin receptor
WO2001010844A1 (en) 1999-08-05 2001-02-15 Meiji Seika Kaisha, Ltd. φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM
US20030199571A1 (en) * 1999-12-24 2003-10-23 Gordon Bruton (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives
EP1170287B1 (en) * 2000-01-25 2003-12-03 Kaneka Corporation Process for preparation of optically active n-substituted azetidine-2-carboxylic acids
DK1381382T3 (en) 2000-11-01 2009-02-02 Merck Patent Gmbh Methods and Preparations for the Treatment of Eye Diseases
CA2449054C (en) 2001-05-30 2011-01-04 The Scripps Research Institute Integrin targeting liposome for nucleic acid delivery
MXPA04000839A (en) * 2001-08-01 2004-05-14 Merck Patent Gesellscahft Mit Integrin inhibitors for the treatment of eye diseases.
MXPA04007770A (en) * 2002-02-14 2004-10-15 Merck Patent Gmbh Methods and compositions for the treatment of eye diseases.
DE10305784A1 (en) * 2003-02-12 2004-08-26 Merck Patent Gmbh 3-Oxo-3,4-dihydro-2H-benz-(1,4)-oxazin-6-yl)-propionic acid derivative preparation, for use as integrin inhibitors with e.g. antitumor action, by multi-stage process giving diastereomerically pure product
DE10337863A1 (en) 2003-08-18 2005-03-17 Merck Patent Gmbh Use of chromene-4-one derivatives
KR101224368B1 (en) * 2004-06-04 2013-01-22 더 스크립스 리서치 인스티튜트 Compositions and methods for treatment of neovascular diseases
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2009331179B2 (en) * 2008-12-26 2014-09-18 Sumitomo Pharma Co., Ltd. Novel bicyclic heterocyclic compound
WO2011024987A1 (en) * 2009-08-31 2011-03-03 塩野義製薬株式会社 Aromatic fused heterocyclic derivative and pharmaceutical composition containing same
WO2015181676A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150550A1 (en) * 1992-12-01 1994-06-09 Melissa S. Egbertson Fibrinogen receptor antagonists
US5741796A (en) * 1994-05-27 1998-04-21 Merck & Co., Inc. Pyridyl and naphthyridyl compounds for inhibiting osteoclast-mediated bone resorption
DE19548709A1 (en) * 1995-12-23 1997-07-03 Merck Patent Gmbh Tyrosine derivatives
DE19654483A1 (en) * 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanine derivatives
EP0907637A1 (en) * 1996-06-28 1999-04-14 MERCK PATENT GmbH Phenylalamine derivatives as integrin inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662339B2 (en) 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
US9403830B2 (en) 2012-07-17 2016-08-02 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US9303018B2 (en) 2013-07-15 2016-04-05 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US9573957B2 (en) 2013-07-15 2017-02-21 Boehringer Ingelheim International Gmbh Inhibitors of leukotriene production
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Also Published As

Publication number Publication date
CN1252064A (en) 2000-05-03
AU735313B2 (en) 2001-07-05
AR010894A1 (en) 2000-07-12
ATE225776T1 (en) 2002-10-15
HUP0001138A3 (en) 2002-10-28
RU2187506C2 (en) 2002-08-20
DE59805895D1 (en) 2002-11-14
CN1085205C (en) 2002-05-22
AU6620698A (en) 1998-09-08
NO993901D0 (en) 1999-08-12
BR9807345A (en) 2000-03-21
TR199901962T2 (en) 1999-12-21
JP4327257B2 (en) 2009-09-09
CZ297366B6 (en) 2006-11-15
SK107199A3 (en) 2000-05-16
PL335101A1 (en) 2000-04-10
CZ287599A3 (en) 1999-11-17
KR20000071030A (en) 2000-11-25
SI0964856T1 (en) 2003-04-30
ZA981178B (en) 1999-05-21
DE19705450A1 (en) 1998-08-20
DK0964856T3 (en) 2003-02-10
HUP0001138A2 (en) 2001-05-28
PT964856E (en) 2003-02-28
CY2341B1 (en) 2004-02-06
CA2280727C (en) 2008-05-06
ID22533A (en) 1999-10-28
SK284646B6 (en) 2005-08-04
EP0964856A1 (en) 1999-12-22
ES2183332T3 (en) 2003-03-16
JP2001511789A (en) 2001-08-14
NO993901L (en) 1999-10-12
WO1998035949A1 (en) 1998-08-20
NO313289B1 (en) 2002-09-09
EP0964856B1 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
CA2280727A1 (en) Bicyclic amino acids
TW372232B (en) Phenylalanine derivatives
RU94013439A (en) HETEROCYCLIC COMPOUNDS, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT
NO986090L (en) Phenylalanine derivatives as integrin inhibitors
UA74346C2 (en) Aminodicarboxylic acids derivatives, use thereof and a medicament
CA2400217A1 (en) Pteridine compounds for the treatment of psoriasis
RU92004368A (en) SUBSTITUTED PYRIMIDINES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION
FI913478A0 (en) DIAZINDERIVAT.
CA2348391A1 (en) Chromenone and chromanone derivatives as integrin inhibitors
HUT63422A (en) Process for producing triazolopyrimidine derivatives and pharmaceutical compositions comprising same
EE03262B1 (en) Alkoxyalkylcarbamates from Imidazo [1,2-a] pyridines, their Preparation and Use
EP0434057A3 (en) Indolocarbazole derivatives, processes for their preparation and their use
EE200200305A (en) Novel azabicyclooctane derivatives used in the treatment of cardiac arrhythmias
WO2000048996A3 (en) β-ALANINE DERIVATIVES
HUP0103712A2 (en) Salts of paroxetine, process for their preparation and their pharmaceutical use
DE69621786D1 (en) AMINOTETRAL IN DERIVATIVE FOR THE TREATMENT OF HEART CIRCULAR DISEASE
HK1050141A1 (en) Inhibitor for 20-hete-yielding enzyme
ATE554764T1 (en) EFFECTIVE SIMPLIFIED DERIVATIVES OF IMMUNOSUPPRESSANTS
MX9604019A (en) Biothyne derivatives.
HUP0303181A2 (en) Use of type 4 phosphodiesterase inhibitors for preparation of pharmaceutical compositions suitable for treating of myocardial diseases
WO1998056759A3 (en) Novel pentaerythrite derivatives, the production and use thereof and intermediate products for the synthesis of the same
MX9600165A (en) 3-alkoxycarbonylthiadiazinonas, process for the preparation thereof and pharmaceutical compositions containing them.
WO2001010841A3 (en) Fluorene derivatives as integrin inhibitors
WO2001021620A3 (en) Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines
HUP0301971A3 (en) Uses of thaliporphine or its derivatives for producing pharmaceutical compositions suitable for treating cardiac diseases and the compounds

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140206